Literature DB >> 11952143

Interferon--gamma control of EBV-transformed B cells: a role for CD8+ T cells that poorly kill EBV-infected cells.

Yan Shi1, Charles T Lutz.   

Abstract

Control of Epstein-Barr virus (EBV) infection requires CD8+ T cells. Surprisingly, many EBV-specific CD8+ T cells kill autologous EBV-transformed B lymphoblasts poorly. We investigated the effector functions used by poorly cytotoxic EBV-specific CD8+ D7 cloned T cells and by EBV-stimulated peripheral blood lymphocytes. D7 T cells did not inhibit B lymphoblast growth in long-term coculture, but prevented the outgrowth of newly infected autologous B cells. Optimally stimulated D7 T cells and EBV-stimulated peripheral blood lymphocytes produced interferon (IFN)-y at levels that inhibited EBV-transformed B cell outgrowth. Inhibitory factor activity was neutralized by anti-IFN-gamma monoclonal antibodies (mAb), but not by antibodies to several other cytokines. These data suggest an in vivo role for IFN-y secreting EBV-specific CD8+ T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11952143     DOI: 10.1089/088282402317340350

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  9 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.

Authors:  Diego Marescotti; Federica Destro; Anna Baldisserotto; Mauro Marastoni; Giuseppe Coppotelli; Maria Masucci; Riccardo Gavioli
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

3.  Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

Authors:  Federica Destro; Fabio Sforza; Mariaconcetta Sicurella; Diego Marescotti; Eleonora Gallerani; Anna Baldisserotto; Mauro Marastoni; Riccardo Gavioli
Journal:  Immunology       Date:  2011-02-22       Impact factor: 7.397

4.  Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.

Authors:  Kui Shin Voo; Tihui Fu; Helen Y Wang; Judy Tellam; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Rong-Fu Wang
Journal:  J Exp Med       Date:  2004-02-09       Impact factor: 14.307

5.  The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.

Authors:  K Jones; L Wockner; R M Brennan; C Keane; P K Chattopadhyay; M Roederer; D A Price; D K Cole; B Hassan; K Beck; D Gottlieb; D S Ritchie; J F Seymour; F Vari; P Crooks; S R Burrows; M K Gandhi
Journal:  Clin Exp Immunol       Date:  2015-11-13       Impact factor: 4.330

6.  Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection.

Authors:  Janice K P Lam; K F Hui; Raymond J Ning; X Q Xu; K H Chan; Alan K S Chiang
Journal:  Front Microbiol       Date:  2018-03-07       Impact factor: 5.640

Review 7.  Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target.

Authors:  Christian Münz
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

8.  Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro.

Authors:  Kara Bickham; Kiera Goodman; Casper Paludan; Sarah Nikiforow; Ming Li Tsang; Ralph M Steinman; Christian Münz
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

9.  Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma.

Authors:  Till Strowig; Fabienne Brilot; Frida Arrey; Gwenola Bougras; Dolca Thomas; William A Muller; Christian Münz
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.